Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 11/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 11/20 | 0.68 |
| ▸ | MAPT | P10636 | 10/20 | 0.63 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | TDP2 | O95551 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL149619 | 0.86 | MEN1 (0.52) | MEN1KMT2AMAPTRAB9AHSD17B10 | |
| SCHEMBL28744558 | 0.81 | MEN1 (0.69) | MEN1KMT2AMAPTRAB9AHSD17B10 | |
| SCHEMBL28941105 | 0.80 | MEN1 (0.44) | MEN1KMT2AMAPT | |
| SCHEMBL125195 | 0.77 | MAPT (1.00) | MEN1KMT2AMAPTRAB9AHSD17B10 | |
| SCHEMBL8441345 | 0.77 | MEN1 (1.00) | MEN1KMT2AMAPTRAB9AHSD17B10 | |
| SCHEMBL20020500 | 0.77 | MEN1 (0.69) | MEN1KMT2AMAPTRAB9AHSD17B10 | |
| SCHEMBL125016 | 0.77 | MEN1 (0.68) | MEN1KMT2AMAPTRAB9AHSD17B10 | |
| SCHEMBL31579482 | 0.76 | MEN1 (0.61) | MEN1KMT2AMAPTRAB9AHSD17B10 | |
| SCHEMBL5906374 | 0.76 | AR (0.60) | MEN1KMT2APOLBGAA | |
| SCHEMBL5906008 | 0.74 | ITGA4 (0.58) | MEN1KMT2AMAPTTDP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118373777-A | Pyrimidine diketone derivative and preparation method and application thereof | 河北科技大学 | 2024-07-23 | — | — | CN | disclosed |
| US-20120059163-A1 | Non-linear opticaly active molecules, their synthesis, and use | OPTIMER PHOTONICS, INC. (US) | 2012-03-08 | — | — | US | disclosed |
| US-20080004415-A1 | Non-linear optically active molecules, their synthesis, and use | OPTIMER PHOTONICS, INC. (US) | 2008-01-03 | — | — | US | disclosed |
| US-20080004415-A1 | Non-linear optically active molecules, their synthesis, and use | OPTIMER PHOTONICS, INC. (US) | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059163-A1 | Non-linear opticaly active molecules, their synthesis, and use | INCENP, CYBA, ADCY5 | MEN1 4480/4885KMT2A 3041/4885MAPT 2242/4885 |
| US-20080004415-A1 | Non-linear optically active molecules, their synthesis, and use | INCENP, CYBA, PAICS | MEN1 4473/4885KMT2A 2961/4885MAPT 2173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.